Literature DB >> 23271292

Caveolin-1 is involved in radiation-induced ERBB2 nuclear transport in breast cancer cells.

Yu Zhang1, Shiying Yu2, Liang Zhuang1, Zu'an Zheng1, Tengfei Chao1, Qiang Fu1.   

Abstract

This study examined the radiation-induced ERBB2 nuclear transport in the BT474 breast cancer cell line and the relationship between caveolin-1 and radiation-induced ERBB2 nuclear transport. The BT474 cells were treated with herceptin (200 nmol/L), PP2 (a caveolin-1 inhibitor, 100 nmol/L) and irradiation combined or alone. Confocal microscopy was used to observe the nuclear import of ERBB2 and caveolin-1 after irradiation. Western blotting was employed to detect the expression of ERBB2, caveolin-1 and DNA-PKcs after irradiation, and immunoprecipitation to identify the ERBB2 and caveolin-1 complex before perinuclear ERBB2 localization. Confocal microscopy showed the transport of ERBB2 and caveolin-1 from the cell membrane to the nucleus 15 min after irradiation and the proteins accumulated at the perinuclear region within 45 min. Western blotting revealed that the expression levels of ERBB2, caveolin-1 and DNA-PKcs were increased after irradiation and reached a peak 45 min later. Both herceptin and PP2 treatments were found to decrease ERBB2 expression. An immune complex composed of ERBB2 and caveolin-1 was found in the herceptin group after irradiation. It was concluded that after irradiation, ERBB2 may be transported from the cell membrane to the nucleus and activate DNA-PKcs to trigger DNA double-strand break (DSB) repair; caveolin-1 may participate in this process. Treatments involving the downregulation of caveolin-1 may increase the radiosensitization of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271292     DOI: 10.1007/s11596-012-1053-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  21 in total

1.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

Authors:  Rita Nahta; Linda X H Yuan; Bing Zhang; Ryuji Kobayashi; Francisco J Esteva
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

2.  Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.

Authors:  Janet K Horton; Jan Halle; Madlyn Ferraro; Lisa Carey; Dominic T Moore; David Ollila; Carolyn I Sartor
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-27       Impact factor: 7.038

3.  ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway.

Authors:  Mahmoud Toulany; Minjmaa Minjgee; Rainer Kehlbach; Jianyong Chen; Michael Baumann; H Peter Rodemann
Journal:  Radiother Oncol       Date:  2010-03-27       Impact factor: 6.280

4.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Authors:  M A Molina; J Codony-Servat; J Albanell; F Rojo; J Arribas; J Baselga
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

5.  Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").

Authors:  Mika Fukutome; Katsuya Maebayashi; Sachiko Nasu; Kaori Seki; Norio Mitsuhashi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-10-01       Impact factor: 7.038

6.  TGFalpha expression impairs Trastuzumab-induced HER2 downregulation.

Authors:  Giorgio Valabrega; Filippo Montemurro; Ivana Sarotto; Annalisa Petrelli; Patrizia Rubini; Carlo Tacchetti; Massimo Aglietta; Paolo Maria Comoglio; Silvia Giordano
Journal:  Oncogene       Date:  2005-04-21       Impact factor: 9.867

7.  Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.

Authors:  Suhail M Ali; Walter P Carney; Francisco J Esteva; Monica Fornier; Lyndsay Harris; Wolfgang J Köstler; Jean-Pierre Lotz; Diana Luftner; Marie-France Pichon; Allan Lipton
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

8.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

Authors:  Cary D Austin; Ann M De Mazière; Paul I Pisacane; Suzanne M van Dijk; Charles Eigenbrot; Mark X Sliwkowski; Judith Klumperman; Richard H Scheller
Journal:  Mol Biol Cell       Date:  2004-09-22       Impact factor: 4.138

9.  Induction of ERBB2 nuclear transport after radiation in breast cancer cells.

Authors:  Bo Luo; Shiying Yu; Liang Zhuang; Shu Xia; Zhen Zhao; Lei Rong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

10.  c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma.

Authors:  Masayuki Akamatsu; Toshiharu Matsumoto; Kuniyuki Oka; Shigetaka Yamasaki; Hiroshi Sonoue; Yoshiaki Kajiyama; Masahiko Tsurumaru; Keisuke Sasai
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

View more
  5 in total

1.  MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2.

Authors:  Teng-Fei Chao; Hui-Hua Xiong; Wei Liu; Yang Chen; Jia-Xuan Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

2.  Caveolae Microdomains Mediate STAT5 Signaling Induced by Insulin in MCF-7 Breast Cancer Cells.

Authors:  Rocio Castillo-Sanchez; Pedro Cortes-Reynosa; Mario Lopez-Perez; Alejandra Garcia-Hernandez; Eduardo Perez Salazar
Journal:  J Membr Biol       Date:  2022-06-25       Impact factor: 1.843

3.  APPL proteins modulate DNA repair and radiation survival of pancreatic carcinoma cells by regulating ATM.

Authors:  J Hennig; M P McShane; N Cordes; I Eke
Journal:  Cell Death Dis       Date:  2014-04-24       Impact factor: 8.469

4.  Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application.

Authors:  Götz Pilarczyk; Ines Nesnidal; Manuel Gunkel; Margund Bach; Felix Bestvater; Michael Hausmann
Journal:  Int J Mol Sci       Date:  2017-02-09       Impact factor: 5.923

5.  Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.

Authors:  Tingting Huang; Xiaoxiao Luo; Bili Wu; Ping Peng; Yuhong Dai; Guangyuan Hu; Hong Qiu; Xianglin Yuan
Journal:  Oncol Rep       Date:  2020-10-21       Impact factor: 3.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.